《即日市评》恒指两连跌 京东健康首挂涨56%
受金融股下滑拖累，港股今日持续回落。市场关注中美关系发展，美股昨晚个别发展，道指跌148点或0.5%，纳指攀升0.5%，执笔之时美汇指数处90.93，道指期货最新跌77点或0.3%、美股纳指期货最新跌18点或0.1%。今早人民币中间价续上调42点报6.5320兑一美元近两年半高，上证综指全日跌0.2%收3,410，沪深两市成交额共7,017亿人民币。
恒指低开46点报26,460点，已为全日高位，其後跌幅曾扩至235点一度低见26,270点，最终全日跌202点或0.8%，收26,304点，连跌两日(累跌531点或2%)；国指全日跌63点或0.6%，收10,409点；恒生科技指数升140点或1.8%，收8,085点。大市全日成交总额1,354.18亿元，沪、深港通南下交易录得净流入金额分别为15.84亿及23.91亿元人民币。
金融股下滑，汇控(00005.HK)股价走低3.6%收41.35元，工行(01398.HK)及中国平安(02318.HK)股价各走低2%及3.4%。
【恒指两股跌 京东健康扬】
市场焦点之一是由京东集团(09618.HK)分拆的京东健康(06618.HK)首日挂牌，股价高开34%报94.5元，早段曾回顺至92.6元，3时左右曾抽升至123.9元，全日收110元，较上市价70.58元，高39.42元或近56%，成交1.565亿股，涉资160亿元。不计手续费，每手50股，账面赚1,971元。京东集团全日股价跌1.8%收325.8元。同业阿里健康(00241.HK)股价扬3.9%收23.9元。
西南证券发表研究报告指，京东健康作为互联网医疗行业後起之秀，其B2C(公司对个人交易)自营电商「京东大药房」、B2B(企业对企业)「药京采」目前均已处於行业领先水，指公司已经实现了在内地基本的互联网医疗基建，随着用户医疗消费习惯的培养、政策的逐渐明朗预计将进入爆发阶段，建议积极关注，但该行无给予投资评级及目标价。
【沽空率下降 小米逆市涨】
港股今日主板市宽转弱，主板股票的升跌比率为17比26(上日为16比27)，下跌1,043只(跌幅2.3%)，恒指成份股今日14只股份上升，下跌股份36只，升跌比率为27比69(上日为75比23)；大市今日录沽空137.54亿元，占可沽空股份成989.82亿元的13.896%(上日为16.549%)。
小米(01810.HK)全日股价弹高4.8%收26.35元。内媒引述消息指，小米旗下智能手机小米11标准版正式获得内地3C(中国强制性产品认证制度)认证，据悉今次手机充电设配55W快充，将全球首配旗舰手机芯片「骁龙888」。业内消息透露，小米11手机最快将於本月末发布。(wl/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
